.
the obvious reason: their big-spending pharmaceutical advertisers would drop them like hot potatoes..
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
.
�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement.